MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer.
Yingying TangShijie TangWenjuan YangZhengyan ZhangTeng WangYuyun WuJunyi XuChristian PilarskyMassimiliano MazzoneLei-Wei WangYong-Wei SunRuijun TianYujie TangYu WangChaochen WangJing XuePublished in: Gut (2024)
In summary, our findings underscore the pivotal role of MED12 in remodelling immnue TME through the epigenetic silencing of retrotransposons, offering a potential therapeutic target for enhancing tumour immunogenicity and overcoming immunotherapy resistance in PDAC.